A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.

Información del proyecto

CLINGLIO

Identificador del acuerdo de subvención: 755179

DOI

10.3030/755179

Proyecto cerrado

Fecha de la firma de la CE 27 Noviembre 2017

Fecha de inicio 1 Diciembre 2017

Fecha de finalización 31 Mayo 2022

Financiado con arreglo a

SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 6 155 125,00

Aportación de la UE

€ 6 155 125,00

6 155 125,00

Coordinado por

LAMINAR PHARMACEUTICALS SA
Spain

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

First regulatory approval of final version of study protocol

Approvals required for invitation / enrolment of first subject in at least one clinical centre: Ethic Committee, Competent Authority and National Data Protection Authority). Registration in Primary Registries in the WHO Registry Network (EU Clinical Trials Register (EU-CTR)).

Study team TCs, newsletters progress/issues reports

According to the communication plan specified in CT project plan (D4.2).Last publicaction will take place on month 36. We expect deliveries also in monots 6, 12, 24 and 30.

Protocols and laboratory manual for miRNAS, mRNA expression and RNAseq
Statistical protocols
Report on the status of posting results

Report on the status of posting results in the study registryies including timelines when final posting of results is scheduled after end of funding period To be scheduled for the time of expected results

Sample protocols for liquid biopsy biomarkers
Protocols for protein biomarker determinations

Protocols for protein biomarker determinations (GFAP, mTOR, pAkt, SMS1, SMS2, etc.).

Consititution of the different management bodies

Constitution of the different management bodies

Role of the membrane lipid composition and lipid genes in glioma cell proliferation

Expression and analysis and patient survival; (ii) Lipidomic and proteomic analysis of proliferating and quiescent glioma (U118) cells; (iii) potential biomarker determinations

SMS1 and SMS2 molecular modelling

(i) determination of SMS1 structure , (ii) determination of SMS2 structure, (iii) determination of SMS1-2OHOA and SMS2-2OHOA interactions, and (iv) determination of the structure and interaction with 2OHOA for specific mutants selected from other experiments in this WP

Publicaciones

Study of the Interaction of a Novel Semi-Synthetic Peptide with Model Lipid Membranes

Autores: Lucia Sessa, Simona Concilio, Peter Walde, Tom Robinson, Petra S. Dittrich, Amalia Porta, Barbara Panunzi, Ugo Caruso, Stefano Piotto
Publicado en: Membranes, Edición 10/10, 2020, Página(s) 294, ISSN 2077-0375
Editor: Molecular Diversity Preservation International
DOI: 10.3390/membranes10100294

Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues

Autores: Doralicia Casares, Pablo V. Escribá, Catalina Ana Rosselló
Publicado en: International Journal of Molecular Sciences, Edición 20/9, 2019, Página(s) 2167, ISSN 1422-0067
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms20092167

The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA

Autores: Paula Fernández-García, Catalina A. Rosselló, Raquel Rodríguez-Lorca, Roberto Beteta-Göbel, Javier Fernández-Díaz, Victoria Lladó, Xavier Busquets, Pablo V. Escribá
Publicado en: Cancers, Edición 11/1, 2019, Página(s) 88, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers11010088

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt

Autores: Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá
Publicado en: Oncotarget, Edición 10/26, 2019, ISSN 1949-2553
Editor: Impact Journals
DOI: 10.18632/oncotarget.26824

Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity

Autores: Wessal Massalha, Mark Markovits, Edward Pichinuk, Yael Feinstein-Rotkopf, Mark Tarshish, Kumudesh Mishra, Victoria Llado, Miguel Weil, Pablo V. Escriba, Or Kakhlon
Publicado en: Bioscience Reports, Edición 39/1, 2019, Página(s) BSR20181661, ISSN 0144-8463
Editor: Kluwer Academic Publishers
DOI: 10.1042/bsr20181661

The Implications for Cells of the Lipid Switches Driven by Protein–Membrane Interactions and the Development of Membrane Lipid Therapy

Autores: Manuel Torres, Catalina Ana Rosselló, Paula Fernández-García, Victoria Lladó, Or Kakhlon, Pablo Vicente Escribá
Publicado en: International Journal of Molecular Sciences, Edición 21/7, 2020, Página(s) 2322, ISSN 1422-0067
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21072322

Derechos de propiedad intelectual

ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG

Número de solicitud/publicación: EP 09831504
Fecha: 2009-12-04
Solicitante(s): UNIVERSITAT DE LES ILLES BALEARS

USE OF HYDROXYOLEIC ACID AND SIMILAR COMPOUNDS IN THE PRODUCTION OF MEDICAMENTS

Número de solicitud/publicación: EP 02783094
Fecha: 2002-10-09
Solicitante(s): UNIVERSITAT DE LES ILLES BALEARS